HUE032744T2 - Oligopeptide-free cell culture medium - Google Patents
Oligopeptide-free cell culture medium Download PDFInfo
- Publication number
- HUE032744T2 HUE032744T2 HUE07702574A HUE07702574A HUE032744T2 HU E032744 T2 HUE032744 T2 HU E032744T2 HU E07702574 A HUE07702574 A HU E07702574A HU E07702574 A HUE07702574 A HU E07702574A HU E032744 T2 HUE032744 T2 HU E032744T2
- Authority
- HU
- Hungary
- Prior art keywords
- cells
- medium
- cell culture
- virus
- cell
- Prior art date
Links
- 239000006143 cell culture medium Substances 0.000 title claims abstract description 44
- 239000002609 medium Substances 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 146
- 238000004113 cell culture Methods 0.000 claims description 14
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 241000271566 Aves Species 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 5
- 206010000210 abortion Diseases 0.000 claims 1
- 231100000176 abortion Toxicity 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 44
- 229920000768 polyamine Polymers 0.000 abstract description 35
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 82
- 239000005700 Putrescine Substances 0.000 description 40
- 108010038807 Oligopeptides Proteins 0.000 description 27
- 102000015636 Oligopeptides Human genes 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 22
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 230000012010 growth Effects 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 14
- 108010054218 Factor VIII Proteins 0.000 description 14
- 102000001690 Factor VIII Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 13
- 229960000301 factor viii Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 11
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 10
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 10
- 229960003104 ornithine Drugs 0.000 description 10
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 10
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 229940063675 spermine Drugs 0.000 description 9
- 210000003501 vero cell Anatomy 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 108010009736 Protein Hydrolysates Proteins 0.000 description 7
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 7
- 229940031098 ethanolamine Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 239000000413 hydrolysate Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000003531 protein hydrolysate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010023321 Factor VII Proteins 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- -1 for example Proteins 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 238000012365 batch cultivation Methods 0.000 description 4
- 230000000035 biogenic effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000001902 propagating effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940063673 spermidine Drugs 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091005670 ADAMTS13 Proteins 0.000 description 2
- 102000043853 ADAMTS13 Human genes 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102000016519 Coagulation factor VII Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 238000011053 TCID50 method Methods 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229940105774 coagulation factor ix Drugs 0.000 description 2
- 229940105772 coagulation factor vii Drugs 0.000 description 2
- 229940105778 coagulation factor viii Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 241000865080 Dermacentor albipictus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000500891 Insecta Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/005—Protein-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75641906P | 2006-01-04 | 2006-01-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE032744T2 true HUE032744T2 (en) | 2017-10-30 |
Family
ID=37942126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE07702574A HUE032744T2 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture medium |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20070212770A1 (enExample) |
| EP (4) | EP3653699A1 (enExample) |
| JP (6) | JP5259418B2 (enExample) |
| KR (2) | KR101423344B1 (enExample) |
| CN (2) | CN102643777A (enExample) |
| AU (1) | AU2007204044B2 (enExample) |
| CA (1) | CA2633306A1 (enExample) |
| CY (1) | CY1119046T1 (enExample) |
| DK (3) | DK2522717T3 (enExample) |
| ES (3) | ES2629304T3 (enExample) |
| HU (1) | HUE032744T2 (enExample) |
| LT (1) | LT1974014T (enExample) |
| PL (3) | PL3121266T3 (enExample) |
| PT (3) | PT3121266T (enExample) |
| RU (3) | RU2486236C2 (enExample) |
| SI (1) | SI2522717T1 (enExample) |
| WO (1) | WO2007077217A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2522717T3 (da) | 2006-01-04 | 2014-04-22 | Baxter Int | Oligopeptid-frie cellekulturmedier |
| PT2574677T (pt) | 2007-12-27 | 2017-10-19 | Baxalta Inc | Processos para cultura de células |
| WO2009088713A1 (en) * | 2007-12-31 | 2009-07-16 | Baxter International Inc. | Substantially animal protein-free recombinant furin and methods for producing same |
| CN102317440B (zh) * | 2008-01-09 | 2014-12-03 | 塞尔卡有限公司 | 改进的培养基添加剂及其应用方法 |
| AU2009244776B2 (en) * | 2008-02-25 | 2013-03-07 | Nanotherapeutics, Inc. | Method for producing continuous cell lines |
| US20100120093A1 (en) * | 2008-11-12 | 2010-05-13 | Baxter International Inc. | Method of Producing Serum-Free Insulin-Free Factor VII |
| KR101574056B1 (ko) | 2009-07-31 | 2015-12-02 | 백스터 인터내셔널 인코포레이티드 | Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지 |
| US8580554B2 (en) * | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
| KR20180095738A (ko) | 2009-09-21 | 2018-08-27 | 박스알타 인코퍼레이티드 | 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 |
| ES2755907T3 (es) | 2010-04-26 | 2020-04-24 | Novartis Ag | Medio de cultivo celular mejorado |
| SG10201809632XA (en) | 2010-07-08 | 2018-12-28 | Baxalta Inc | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE |
| MX351706B (es) | 2010-09-17 | 2017-10-25 | Baxalta Inc | Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro. |
| PL3260132T3 (pl) | 2010-10-27 | 2022-08-08 | Takeda Pharmaceutical Company Limited | Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| AR086904A1 (es) | 2011-06-10 | 2014-01-29 | Baxter Int | Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf) |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CN104822826B (zh) | 2012-10-15 | 2019-04-30 | 百时美施贵宝公司 | 用于蛋白产生的哺乳动物细胞培养过程 |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| KR101641655B1 (ko) * | 2014-01-08 | 2016-07-21 | 서울대학교산학협력단 | 스퍼미딘 또는 스퍼민을 이용함으로써 생육 저해제에 대한 내성이 증진된 효모의 배양방법 |
| KR20170129808A (ko) * | 2015-03-17 | 2017-11-27 | 디에스엠 아이피 어셋츠 비.브이. | 다이아미노부탄의 제조 방법 |
| JP6624985B2 (ja) * | 2015-03-27 | 2019-12-25 | 日清ファルマ株式会社 | ポリアミン高含有酵母 |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| ES2803773T3 (es) | 2015-12-02 | 2021-01-29 | CSL Behring Lengnau AG | Medios mejorados para la expresión de proteínas recombinantes dependientes de vitamina k |
| CN106635953B (zh) * | 2016-12-13 | 2021-02-19 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
| KR102782655B1 (ko) * | 2017-07-06 | 2025-03-14 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| AU2018298232B2 (en) | 2017-07-07 | 2025-04-03 | Takeda Pharmaceutical Company Limited | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF |
| US10632176B2 (en) | 2017-07-07 | 2020-04-28 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
| EA202092223A1 (ru) | 2018-03-21 | 2021-02-10 | Баксалта Инкорпорейтед | Разделение vwf и пропептида vwf хроматографическими методами |
| CN112041673A (zh) | 2018-04-20 | 2020-12-04 | 詹森生物科技公司 | 色谱柱鉴定的转变分析方法 |
| CN108872758B (zh) * | 2018-05-10 | 2019-06-28 | 江苏大学 | 一种电子元器件寿命检测装置 |
| US11634499B2 (en) | 2018-11-13 | 2023-04-25 | Janssen Biotech, Inc. | Control of trace metals during production of anti-CD38 antibodies |
| CN113227354A (zh) | 2019-01-17 | 2021-08-06 | 勃林格殷格翰动物保健美国公司 | 用于禽类疫苗生产的无血清培养基及其用途 |
| CN113645993A (zh) | 2019-02-01 | 2021-11-12 | 武田药品工业株式会社 | 使用重组VWF(rVWF)进行预防性治疗的方法 |
| EP3938392A1 (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
| EP3938384A4 (en) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | PREPARATION PROCEDURES FOR THE PREPARATION OF ANTI-IL12/IL23 ANTIBODY COMPOSITIONS |
| US12180271B2 (en) | 2019-03-14 | 2024-12-31 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-TNF antibody compositions |
| JP7635137B2 (ja) | 2019-03-14 | 2025-02-25 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｔｎｆ抗体組成物を産生するための方法 |
| EP3947632A1 (en) | 2019-04-01 | 2022-02-09 | The Automation Partnership (Cambridge) Ltd. | Operation process for a cell cultivation system |
| JP2022547556A (ja) | 2019-09-11 | 2022-11-14 | 武田薬品工業株式会社 | フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN114667351A (zh) * | 2019-11-05 | 2022-06-24 | 味之素株式会社 | 蛋白质的制造方法 |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| CN115335074A (zh) | 2020-02-04 | 2022-11-11 | 武田药品工业株式会社 | 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多 |
| CN115836126A (zh) | 2020-04-02 | 2023-03-21 | 武田药品工业株式会社 | Adamts13变体、组合物及其用途 |
| CA3182893A1 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| WO2022159432A1 (en) | 2021-01-20 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| CN113151183A (zh) * | 2021-04-21 | 2021-07-23 | 赵峻岭 | 一种促进蛋白表达的培养基添加物及其应用 |
| US20230042465A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
| JP2024527581A (ja) | 2021-07-09 | 2024-07-25 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法 |
| CN119053625A (zh) | 2022-03-02 | 2024-11-29 | 瑞泽恩制药公司 | 用于抗体生产的细胞培养方法 |
| CA3266599A1 (en) | 2022-09-07 | 2024-11-07 | Quantitative Biosciences, Inc. | UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST |
| WO2025053166A1 (ja) * | 2023-09-05 | 2025-03-13 | 味の素株式会社 | 培地組成物 |
| WO2025128343A1 (en) | 2023-12-11 | 2025-06-19 | Just-Evotec Biologics, Inc. | Protein expression using trans-splicing and split selectable markers |
| WO2025210223A1 (en) * | 2024-04-04 | 2025-10-09 | Sartorius Xell GmbH | Methods for viral vector production with reduced host cell aggregation and methods for dissolving host cell aggregates |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT165999B (de) | 1947-06-26 | 1950-05-25 | Delle Atel Const Electr | Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom |
| US4443540A (en) * | 1980-05-09 | 1984-04-17 | University Of Illinois Foundation | Protein hydrolysis |
| DK207980A (da) * | 1980-05-13 | 1981-11-14 | Novo Industri As | Fremgangsmaade til fremstilling af et skumnings- eller emulgeringsmiddel paa sojaproteinbasis |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| FR2543158B1 (fr) | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| WO1986004920A1 (en) | 1985-02-13 | 1986-08-28 | Biotechnology Research Partners, Limited | Human metallothionein-ii promoter in mammalian expression system |
| US4978616A (en) * | 1985-02-28 | 1990-12-18 | Verax Corporation | Fluidized cell cultivation process |
| EP0318487B1 (en) | 1986-08-04 | 1993-10-13 | The University Of New South Wales | Serum free tissue culture medium containing polymeric cell-protective agent |
| US5045468A (en) | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
| KR890701731A (ko) | 1987-06-30 | 1989-12-21 | 로버트 디. 웨이스트 | 칼리크레인의 제조방법 |
| JP2507882B2 (ja) | 1988-02-17 | 1996-06-19 | 工業技術院長 | 外部増殖因子非依存性増殖良好細胞株の製造法 |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5573937A (en) * | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| AU653927B2 (en) | 1990-01-22 | 1994-10-20 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Co-independent growth medium for maintenance and propagation of cells |
| JP2844484B2 (ja) | 1990-02-22 | 1999-01-06 | 味の素株式会社 | 組換え蛋白質の生産方法 |
| JP2859679B2 (ja) | 1990-03-01 | 1999-02-17 | 協和醗酵工業株式会社 | 新規細胞株 |
| US5378612A (en) * | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
| JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| AU643077B2 (en) | 1990-10-19 | 1993-11-04 | Unilever Plc | Detergent compositions |
| JPH04228066A (ja) | 1990-10-23 | 1992-08-18 | Rikagaku Kenkyusho | 外来遺伝子発現用培養細胞 |
| EP0531562A1 (de) * | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Kultivierung von Säugetierzellen |
| CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| JPH05123178A (ja) | 1991-11-01 | 1993-05-21 | Ajinomoto Co Inc | Ｌ−フエニルアラニンの製造法 |
| DE4313620A1 (de) | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamsterzellinien und Verfahren zur Glykoproteingewinnung |
| AU7895898A (en) | 1993-04-26 | 1998-10-08 | Hans Wolf | Mammal cell lines and method of obtaining glycoproteins |
| GB9311132D0 (en) * | 1993-05-28 | 1993-07-14 | Eisai London Res Lab Ltd | Control of cell death |
| US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
| JP2766165B2 (ja) | 1993-08-02 | 1998-06-18 | 株式会社バイオポリマー・リサーチ | バクテリアセルロースの製造方法 |
| US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
| EP0653487A1 (de) | 1993-11-07 | 1995-05-17 | Ferruccio Dr. Messi | Serum- und proteinfrei wachsende Zellen |
| US5719050A (en) | 1993-12-24 | 1998-02-17 | Eiken Chemical Co., Ltd. | Animal cell culturing media containing N-acetyl-L-glutamic acid |
| US5498599A (en) * | 1994-01-21 | 1996-03-12 | Amgen Inc. | Methods for stimulating platelet production |
| EP0666312A1 (en) * | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
| WO1996007730A2 (de) | 1994-09-09 | 1996-03-14 | Renner Wolfgang A | Chemisches verfahren zur förderung der proliferation von tierischen zellen |
| CA2415990C (en) | 1994-11-10 | 2009-07-07 | Immuno Aktiengesellschaft | Method for producing biologicals in protein-free culture |
| AT403167B (de) | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
| AU4302796A (en) | 1994-12-16 | 1996-07-03 | Novartis Ag | Production of recombinant secretory component |
| US5741705A (en) * | 1995-02-23 | 1998-04-21 | Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. | Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides |
| EP0811056B1 (en) | 1995-02-23 | 2000-05-31 | Quest International B.V. | Peptides for tissue and cell culture media |
| WO1996040866A1 (en) | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
| AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
| US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| WO1998058050A1 (en) | 1996-08-30 | 1998-12-23 | The University Of North Carolina At Chapel Hill | Immortalized human hepatic cell line and method of making the same |
| EP2221361A3 (en) | 1996-08-30 | 2011-02-09 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
| ATE399855T1 (de) | 1996-10-10 | 2008-07-15 | Invitrogen Corp | Tierzellkulturmedium mit pflanzlichen nährstoffen |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| EP1849860B1 (en) | 1997-05-28 | 2010-11-17 | Novartis Vaccines and Diagnostics S.r.l. | Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| CN1151258C (zh) | 1997-07-23 | 2004-05-26 | 罗切诊断学有限公司 | 通过内源基因活化制备促红细胞生成素 |
| WO1999026470A1 (en) | 1997-11-20 | 1999-06-03 | Weyerhaeuser Company | Nutritive media and manufactured seeds comprising same |
| EP1045898A2 (en) | 1998-01-12 | 2000-10-25 | Betagene, Inc. | Compositions and methods for regulated secretion from neuroendocrine cell lines |
| FR2775983B1 (fr) | 1998-03-13 | 2000-11-10 | Pasteur Merieux Serums Vacc | Milieu et procede de propagation et de multiplication virales |
| WO1999057246A1 (en) | 1998-05-01 | 1999-11-11 | Life Technologies, Inc. | Animal cell culture media comprising non-animal or plant-derived nutrients |
| US6537782B1 (en) * | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
| JP4266055B2 (ja) | 1999-03-04 | 2009-05-20 | 雪印乳業株式会社 | ポリアミン組成物の製造法 |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| ATE330003T1 (de) | 1999-08-05 | 2006-07-15 | Baxter Ag | Rekombinanter stabiler zellklon, seine herstellung und verwendung |
| CA2383073A1 (en) | 1999-08-25 | 2001-03-01 | Immunex Corporation | Compositions and methods for improved cell culture |
| US6596526B1 (en) * | 2000-06-09 | 2003-07-22 | Baxter Aktiengesellschaft | Furin polypeptides with improved characteristics |
| CN1582333B (zh) | 2000-09-25 | 2010-06-16 | 波利门科学生物免疫研究有限公司 | 活疫苗及生产方法 |
| EP1208966A1 (en) | 2000-11-27 | 2002-05-29 | Cheng-Kun Liao | Manufacturing process of patio tabletop glass with broken protection |
| DE10059175A1 (de) | 2000-11-29 | 2002-06-20 | Siemens Ag | Verfahren und Vorrichtung zur Anrufumleitung mittels eines Stellvertreters in einem Kommunikationssystem |
| US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| US6734289B2 (en) * | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
| US20030087372A1 (en) | 2001-06-13 | 2003-05-08 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| WO2003016492A2 (en) * | 2001-08-16 | 2003-02-27 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
| CA2460206C (en) | 2001-10-02 | 2012-01-24 | Novo Nordisk Health Care Ag | Method for production of recombinant proteins in eukaryote cells |
| US20030104527A1 (en) * | 2001-12-03 | 2003-06-05 | National Research Council Of Canada | Methylotrophic bacterium for the production of recombinant proteins and other products |
| DE10161412A1 (de) | 2001-12-13 | 2003-07-03 | Aventis Pharma Gmbh | Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität |
| CN100591759C (zh) * | 2002-07-09 | 2010-02-24 | 巴克斯特国际有限公司 | 用于细胞培养的无动物蛋白质培养基 |
| FR2846004B1 (fr) | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol |
| FR2846005B1 (fr) | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | Composition pour milieu biologique comprenant de l'erythorbate de sodium |
| DE10333675A1 (de) | 2003-07-24 | 2005-03-03 | Aventis Pharma Deutschland Gmbh | Perfusionsverfahren für die Produktion von Erythropoietin |
| EP1673452B1 (en) | 2003-10-10 | 2015-12-23 | Novo Nordisk Health Care AG | Method for large-scale production of a polypeptide in eukaryote cells |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| CA2585547A1 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
| DK2522717T3 (da) | 2006-01-04 | 2014-04-22 | Baxter Int | Oligopeptid-frie cellekulturmedier |
-
2007
- 2007-01-03 DK DK12160789T patent/DK2522717T3/da active
- 2007-01-03 JP JP2008548995A patent/JP5259418B2/ja active Active
- 2007-01-03 DK DK16183987.3T patent/DK3121266T3/da active
- 2007-01-03 EP EP19214402.0A patent/EP3653699A1/en active Pending
- 2007-01-03 RU RU2008131953/10A patent/RU2486236C2/ru active
- 2007-01-03 PL PL16183987T patent/PL3121266T3/pl unknown
- 2007-01-03 PT PT161839873T patent/PT3121266T/pt unknown
- 2007-01-03 SI SI200731439T patent/SI2522717T1/sl unknown
- 2007-01-03 EP EP07702574.0A patent/EP1974014B1/en not_active Revoked
- 2007-01-03 EP EP20120160789 patent/EP2522717B1/en not_active Revoked
- 2007-01-03 HU HUE07702574A patent/HUE032744T2/en unknown
- 2007-01-03 PT PT121607899T patent/PT2522717E/pt unknown
- 2007-01-03 ES ES07702574.0T patent/ES2629304T3/es active Active
- 2007-01-03 CN CN2012100603866A patent/CN102643777A/zh active Pending
- 2007-01-03 EP EP16183987.3A patent/EP3121266B8/en not_active Revoked
- 2007-01-03 CA CA002633306A patent/CA2633306A1/en not_active Abandoned
- 2007-01-03 PL PL07702574T patent/PL1974014T3/pl unknown
- 2007-01-03 KR KR1020087018889A patent/KR101423344B1/ko active Active
- 2007-01-03 ES ES16183987T patent/ES2790887T3/es active Active
- 2007-01-03 KR KR1020137022322A patent/KR101422435B1/ko active Active
- 2007-01-03 LT LTEP07702574.0T patent/LT1974014T/lt unknown
- 2007-01-03 ES ES12160789.9T patent/ES2474573T3/es active Active
- 2007-01-03 PT PT77025740T patent/PT1974014T/pt unknown
- 2007-01-03 AU AU2007204044A patent/AU2007204044B2/en active Active
- 2007-01-03 US US11/649,694 patent/US20070212770A1/en not_active Abandoned
- 2007-01-03 PL PL12160789T patent/PL2522717T3/pl unknown
- 2007-01-03 CN CNA2007800017871A patent/CN101360820A/zh active Pending
- 2007-01-03 DK DK07702574.0T patent/DK1974014T3/en active
- 2007-01-03 WO PCT/EP2007/000027 patent/WO2007077217A2/en not_active Ceased
-
2011
- 2011-02-25 US US13/035,696 patent/US20110151512A1/en not_active Abandoned
-
2013
- 2013-03-01 JP JP2013040650A patent/JP2013106616A/ja not_active Withdrawn
- 2013-03-18 RU RU2013112019A patent/RU2642269C9/ru active
-
2014
- 2014-10-15 JP JP2014210677A patent/JP2015006209A/ja not_active Withdrawn
-
2015
- 2015-11-16 US US14/942,771 patent/US9758568B2/en not_active Expired - Fee Related
-
2016
- 2016-12-28 JP JP2016254914A patent/JP6567490B2/ja active Active
-
2017
- 2017-06-07 CY CY20171100596T patent/CY1119046T1/el unknown
- 2017-08-07 US US15/670,217 patent/US10696731B2/en active Active
- 2017-12-18 RU RU2017144220A patent/RU2758802C2/ru not_active Application Discontinuation
-
2018
- 2018-01-09 JP JP2018001241A patent/JP2018075032A/ja not_active Withdrawn
-
2019
- 2019-11-29 JP JP2019216735A patent/JP7134157B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10696731B2 (en) | Oligopeptide-free cell culture media | |
| EP2213725B2 (en) | Animal protein-free media for cultivation of cells | |
| HK40026826A (en) | Oligopeptide-free cell culture media | |
| HK1177950B (en) | Oligopeptide-free cell culture media | |
| HK1174951A (en) | Oligopeptide-free cell culture media | |
| HK1147110B (en) | Animal protein-free media for cultivation of cells |